Drugs / Gamma-PN3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06562790 | Aug 2024 → Mar 2025 | streptococcal pneumonia | GPN Vaccines | Completed | No outcome recorded |
| Phase 1 | NCT05667740 | Jan → Oct 2023 | pneumococcal infection | GPN Vaccines | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05982314 | Jul 2023 → Aug 2024 | pneumococcal infection | GPN Vaccines | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gamma-PN3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05982314 ↗ |
| Modality | Vaccine | “Inactivated whole-cell pneumococcal vaccine” NCT05667740 ↗ |
| Route | Intramuscular | “500, 1000 or 1500 µg by IM injection on Days 1 and 29” NCT06562790 ↗ |